Financings Of The Fortnight: Notable Uptick In Series A Rounds So Far In 2013
This article was originally published in The Pink Sheet Daily
A strong second half of 2013 could mean a pace of start-up formation not seen since before 2007-2008. Plus news on recent financings by Prosensa, MannKind, OncoEthix and Cardio3 Biosciences.
You may also be interested in...
Epigenetic modifiers are targeting a widening range of indications as growing knowledge of the underlying biology enables improved agents and therapeutic strategies. Nonetheless, issues of selectivity, toxicity, and finding adequate biomarkers still prevent the field from reaching its full potential.
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
Two $1bn+ alliances were penned in October. Financing reached $7.7bn in biopharma, $636m in device, and $140m in diagnostics.